Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease

References

• Wolf G, Neilson EG. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990;259:F768-F777.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Craver C, Belk KW, et al. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US. J Med Econ 2015a;18:303-11
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Matter S, Chawla A, et al. Burden of autosomal dominant polycystic kidney disease: systematic literature review. Am J Pharm Benef 2015b;7:e27-e36
   Google Scholar
• Blanchette CM, Liang C, Lubeck D, et al. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. Drugs Context 2015c;4:3-15
   Google Scholar
• Lentine KL, Xiao H, Machnicki G. Renal function and health care costs in patients with polycystic kidney disease. Clin J Am Soc Nephrol 2010;5:1471-9
   PubMed Web of Science ®Google Scholar
• Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. L Am Soc Nephrol 2001;12:194-200
   PubMed Web of Science ®Google Scholar
• Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008;3:1197-204
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18
   PubMed Web of Science ®Google Scholar
• Ozkok A, Akpinar TS, Tufan F, et al. Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol 2013;17:345-51
   PubMed Web of Science ®Google Scholar
• Woon C, Bielinski-Bradbury A, O’Reilly K, et al. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol 2015;16:1-16
   Web of Science ®Google Scholar
• Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc 2002;288:2421-31
   PubMed Web of Science ®Google Scholar
• Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990;38:1177-80
   PubMed Web of Science ®Google Scholar
• Gonzalo A, Gallego A, Rivera M, et al. Influence of hypertension on early renal insufficiency in autosomal dominant polycystic kidney disease. Nephron 1996;72:225-30
   PubMed Web of Science ®Google Scholar
• Schrier RW, Abebe KZ, Peronne RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 2014;371:2255-66
   PubMed Web of Science ®Google Scholar
• Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381-8
   PubMed Web of Science ®Google Scholar
• Al-Nimri MA, Komers R, Oyama TT, et al. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003;63:1776-84
   PubMed Web of Science ®Google Scholar
• Chapman AB, Johnson A, Gabow PA, et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091-6
   PubMed Web of Science ®Google Scholar
• Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 2014;371:2267-76
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9
   PubMed Web of Science ®Google Scholar
• Mann JF, Shmieder R, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ontarget study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Baur B, Meaney C. Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy 2014;34:613
   Web of Science ®Google Scholar
• Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in glomerular filtration rate during treatment with losartan predicts a slower decrease in long term renal function. Kidney Int 2011;80:282-7
   PubMed Web of Science ®Google Scholar
• O’Hare AM, Bertenthal D, Covinsky KE, et al. Mortality risk stratification in chronic kidney disease: one size for all ages? J Am Soc Nephrol 2006;17:846-53
   PubMed Web of Science ®Google Scholar
• Cipparone CW, Withian-Leitch M, Kimminau KS, et al. Inaccuracy of ICD-9 codes for chronic kidney disease: a study from two practice-based research networks (PBRNs). JABFM 2015;28:678-82
   PubMed Web of Science ®Google Scholar
• United Network for Organ Sharing. Estimated U.S. average 2011 billed charges per transplant. Transplant Living, 2016. https://transplantliving.org/before-the-transplant/financing-a-transplant/the-costs/. Accessed November 10, 2016
   Google Scholar
• Smith LA, Bukanov NO, Hussen H, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 2006;17:2821-31
   PubMed Web of Science ®Google Scholar
• Amro OW, Perrone RD. Patients with autosomal dominant polycystic kidney disease. Semin Dialysis 2015;28:470-3
   PubMed Web of Science ®Google Scholar
• Boucher C, Sandford R. Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2). Eur J Human Genet 2004;12:347-54
   PubMed Web of Science ®Google Scholar
• Davies F, Coles GA, Harper PS, et al. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991;79:477-85
   PubMedGoogle Scholar
• Sands JJ. Disease management improves end-stage renal disease outcomes. Blood Purif 2006;24:394-9
   PubMed Web of Science ®Google Scholar
• Chapman AB, Schrier RW. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 1991;11:653-60
   PubMed Web of Science ®Google Scholar
• Milutinovic J, Fialkow PJ, Agodoa LY, et al. Autosomal dominant polycystic kidney disease: symptoms and clinical findings. Q J Med 1984;53:511-22.
   PubMedGoogle Scholar
• Harrap SB, Davies DL, Macnicol AM, et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501-8
   PubMed Web of Science ®Google Scholar
• Barrett BJ, Foley R, Morgan J, et al. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994;46:1118-23
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379:165-80
   PubMed Web of Science ®Google Scholar
• Hildebrant F. Genetic kidney disease. Lancet 2010;375:1287-95
   PubMed Web of Science ®Google Scholar
• Fick GM, Johnson AM, Hammond WS, et al. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048-56
   PubMed Web of Science ®Google Scholar
• Waheed S, Matsushita K, Astor BC, et al. Combined association of creatinine, albuminuria, and cystatin c with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol 2013;8:434-42.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Schrier R. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology 2006;11:124-30
   PubMed Web of Science ®Google Scholar
• Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal dominant-polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 2003;64:1035-45
   PubMed Web of Science ®Google Scholar